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background Management of uncomplicated 
Plasmodium falciparum malaria relies on artemisinin-
based combination therapies (ACTs). These highly 
effective regimens have contributed to reductions in 
malaria morbidity and mortality. However, artemisinin 
resistance in Asia and changing parasite susceptibility 
to ACT in Africa have now been well documented. 
Strategies that retain current ACT as efficacious 
treatments are urgently needed.
Methods We present an open-label, randomised 
three-arm clinical trial protocol in three African 
settings representative of varying malaria 
epidemiology to investigate whether prolonged ACT-
based regimens using currently available formulations 
can eliminate potentially resistant parasites. The 
protocol investigates whether a sequential course 
of two licensed ACT in 1080 children aged 6–120 
months exhibits superior efficacy against acute P. 
falciparum malaria and non-inferior safety compared 
with standard single-course ACT given to 540 children. 
The primary endpoint is PCR-corrected clinical and 
parasitological response at day 42 or day 63 of follow-
up. Persistence of PCR-detectable parasitaemia at day 
3 is analysed as a key covariate. Secondary endpoints 
include gametocytaemia, occurrence of treatment-
related adverse events in the double-ACT versus 
single-ACT arms, carriage of molecular markers of 
drug resistance, drug kinetics and patient adherence 
to treatment.
Discussion This protocol addresses efficacy and 
safety of sequential ACT regimens in P. falciparum 
malaria in Africa. The approach is designed to extend 
the useful life of this class of antimalarials with 
maximal impact and minimal delay, by deploying 
licensed medicines that could be swiftly implemented 
as sequential double ACT by National Malaria Control 
Programmes, before emerging drug resistance in 
Africa becomes a major threat to public health.
bAckgrounD 
Artemisinin-based combination therapy 
(ACT) is currently the preferred option to 
treat uncomplicated falciparum malaria.1 
Emergence in the greater Mekong subre-
gion of new genotypes of Plasmodium 
falciparum, characterised by sequence 
variants of the P. falciparum kelch 13 
propeller domain protein and reduced 
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Key questions
What is already known on this topic ?
 ► Although still effective, there is increasing concern 
that antimalarial treatment with artemisinin-based 
combination therapy (ACT) is seriously threatened 
by emerging drug resistance.
What is the purpose of this protocol?
 ► This protocol outlines an open-label, randomised 
three-arm clinical trial in three African settings 
representative of varying malaria epidemiology to 
evaluate the  efficacy and safety of two sequential 
ACT regimens as a strategy to prevent persistence 
of Plasmodium falciparum parasites in treated 
malaria patients.
recommendations for policy
 ► The proposed study aims to provide the 
evidence  base for rapidly implementing sequential 
double  ACT treatment if resistance emerges in 
Africa.
2 Schallig HDFH, et al. BMJ Glob Health 2017;2:e000371. doi:10.1136/bmjgh-2017-000371
BMJ Global Health
Figure 1 Clinical trial time line: modelling component drug 
pharmacokinetics for sequential double ACT treatment. 
Pharmacokinetic representation of the rationale for 
sequential double ACT. Artemether–lumefantrine followed 
by DHA is depicted as an example. Pharmacokinetic 
profiles for (A) 0–7 days and (B) 0–42 days after first 
dose. Artemether (80 mg x 6, 0–60 hours) and resulting 
DHA, lumefantrine (480 mg x 6, 0–60 hours), DHA (80 
mg x 3, 72–120 hours) and piperaquine (960 mg x 3, 
72–120 hours). Peripheral concentration for lumefantrine 
is shown on the right y-axis; all other compounds on 
the left y-axis. Artemether is rapidly metabolised to 
DHA, but both components have antiparasitic activity.38 
Modelling parameters are based on published figures 
for combination-treated adults.39 40 ACT, artemisinin-
based combination therapy; conc, concentration; DHA, 
dihydroartemisinin.
susceptibility to artemisinin in vivo and in vitro, is a 
major concern for global public health.1–3 Although 
it has not yet been documented that such parasites 
occur in Africa,4 5 recent data from Burkina Faso and 
Uganda show diminished efficacy of certain ACT 
combinations.6–8 Furthermore, declining respon-
siveness of P. falciparum to ACT has been reported 
from Kenya, linked to submicroscopic persistence of 
P. falciparum and subsequent parasite recrudescence 
weeks after apparently successful treatment of clin-
ical malaria with ACT.9 10 These persistent parasites 
bear clear signals of selection on a number of genes, 
but not Pfk13.5 11 12 The recent observations of dihy-
droartemisinin–piperaquine (DHA-PIP) treatment 
failure in Asia, and in one African isolate, empha-
sise the urgency of response, as DHA-PIP is more 
widely deployed in Africa.13–15 Finally, malaria cases 
imported from Africa to Europe that failed to clear 
following standard treatment artemether–lumefan-
trine (AL) have also recently been reported.16 17
Currently, there are no novel treatment regimens avail-
able in the global drug development portfolio that could 
completely replace ACT should a fall in efficacy occur 
widely. Therefore, it is crucial to preserve the current 
drugs as long as possible.18 Studies in Cambodia with 
prolonged artemisinin treatment demonstrated efficacy 
in areas where standard 3-day treatments are failing, and 
this may provide an interim solution to preserve ACT 
efficacy long enough for novel drugs to ‘catch up’.19–21 
For falciparum malaria in Africa, prolonged artemis-
inin treatment may prevent submicroscopic parasite 
persistence beyond day 3. We propose that sequential 
administration of two ACTs with different partner drugs 
is a parsimonious way to achieve prolonged artemis-
inin treatment.18 22 The rationale behind this proposal, 
‘sequential double ACT’, is:
 ► efficacy in preventing persistent parasitaemia should be 
maximised because following the extended 6-day ex-
posure to artemisinin, parasites will continue also to 
encounter both partner drugs. This is exemplified in 
Figure 1, which models component pharmacokinet-
ics when a full course of AL is followed by a full course 
of DHA-PIP;
 ► transmission potential should be minimised, by the 
same argument;
 ► safety risks are minimised because artemisinin admin-
istered for up to 7 days has an acceptable safety pro-
file, but few partner drugs have been evaluated for 
safety beyond 3 days; sequential use of two well-toler-
ated ACTs means no single partner drug is given for 
more than 3 days;
 ► implementation can be expedited if necessary, as the 
stringent regulatory requirements prerequisite for 
new treatments will not apply.
An additional benefit of sequential double ACT is 
that partner drugs known to exert opposite genetic 
selection on ACT-resistance-associated loci can be 
juxtaposed.23
Design AnD MethoDs
trial design
To investigate the efficacy and safety of sequential 
double ACT over 6 days for treatment of uncomplicated 
P. falciparum malaria in African children, open-label 
randomised clinical trials will be performed in three 
malaria epidemiologically representative African 
settings:
 ► perennial, moderate P. falciparum transmission (Lake 
Victoria hinterland, Kenya)
 ► high seasonal P. falciparum transmission (West African 
Sahel, Burkina Faso)
 ► low-intermittent perennial transmission (East African 
lowland savannah, Tanzania).
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Children (6 months to 10 years) meeting defined 
enrolment criteria will be randomised into three arms:
 ► Arm 1: First-line ACT, according to government 
guidelines in the participating country. In Kenya and 
Tanzania: AL; in Burkina Faso: artesunate–amodi-
aquine (ASAQ);
 ► Arm 2: First-line ACT, according to government 
guidelines in the participating country, followed by 
the approved second-line ACT line. In Kenya and 
Tanzania: AL followed by DHA-PIP; in Burkina Faso: 
ASAQ followed by AL;
 ► Arm 3: The same regimens as in arm 2, but in reverse 
order (second-line ACT followed by first-line ACT).
 ► Dosage in all arms will follow the WHO guidelines for 
each regimen.24
Enrolment criteria follow previous studies,25 26 but can 
be summarised as follows:
 ► Inclusion: children 6–120 months old attending the 
health facilities with microscopy-confirmed uncom-
plicated falciparum malaria; asexual parasite densities 
between 2000 and 200 000/µL; body weight >5 kg; fe-
ver (axillary temperature ≥37.5°C) or history of fever 
in the preceding 24 hours.
 ► Exclusion: signs of severe malaria; haemoglobin 
(Hb) <7 g/dL; acute malnutrition (weight for 
height <70% of the median National Center for 
Health Statistics/WHO reference); any other con-
comitant illness or underlying disease; contraindica-
tion for trial drugs.
objectives
The trial has the following study objectives.
1. Primary study objective
Investigate, using a superiority analysis, whether 
sequential use of the first-line ACT followed imme-
diately by an established second-line ACT, in either 
order of use, is more effective in reducing patent 
or submicroscopic parasite recurrence than is the 
first-line regimen alone; day 3 quantitative (qPCR) 
positivity will be analysed as a key covariate in each 
arm.27
2. Secondary objective
Investigate, using a non-inferiority analysis, whether 
sequential use of two ACT regimens leads to a differ-
ence in frequency of drug-related adverse events 
(AEs) compared with the first-line regimen alone.
3. Exploratory objectives
 ► assess efficacy of the proposed ACT regimens on 
(sub)microscopic transmissible gametocytes;
 ► identify persistent parasitaemia at days 28 and 42 
(and day 63 for low transmission setting) by para-
site DNA detection methods;
 ► evaluate genotypes of persisting parasites at loci 
of interest: Pfk13, Pfcrt, Pfmdr1, Pfap2mu, Pfubp1 
and any subsequently validated markers for drug 
susceptibility;
 ► compare kinetics of artemisinin and partner drugs 
among patients in the three study arms;
 ► assess acceptability and adherence to each 
regimen by health practitioners, patients and 
caregivers.
sample size
The sample size for this trial is based on a previous study 
showing that 30%–40% of Kenyan patients had submi-
croscopic parasite persistence at day 3 determined by 
qPCR.10 27 Therefore, for every 150 children receiving 
a single ACT, we expect that 45–60 children will have 
persistent day 3 parasitaemia by parasite DNA detection, 
of whom about 20 will also have recurrent microscopi-
cally determined parasitaemia at day 28 or 42 (or day 63 
for low transmission setting). Thus, 13.3% of the original 
enrolment will be both day 3 positive by qPCR and day 
28/42 positive by microscopy. Using a conservative predic-
tion that 60% of recurrent parasitaemia at day 28/42 will 
be in those with day 3 subpatent carriage (compared with 
84% previously observed in Kenya10), we hypothesise that 
in the pooled arms receiving two sequential ACTs, this 
proportion will be reduced to 20%, compared with 60% 
in the single-ACT arm. This efficacy-based sample size 
yields excellent power for the primary endpoint even after 
stratification by day 3 PCR positivity (α=0.05—two-sided; 
power: 0.9998); we plan to enrol 180 children per arm 
(to compensate for 20% lost to follow-up). At 80% power, 
we can detect a smaller reduction from 60% recurrence 
at day 28/42% to 34%. With the secondary endpoint of 
PCR detection of recurrent parasitaemia at day 28/42, the 
power of these analyses is increased further. Total sample 
size for the three sites will therefore be 540 (single ACT) vs 
1080 (sequential double ACT in different combinations), 
giving substantial power for pooled (secondary) analyses. 
To summarise:
 ► for an effect size of 40% reduction in recurrent par-
asitaemia, at α=0.05, >99.9% power is achieved with 
group sizes of 540 (single ACT) vs 1080 (sequential 
double ACT, combined)
 ► for 80% power, at α=0.05, an effect size of 26% reduc-
tion in recurrent parasitaemia would be detected with 
these group sizes
In each site, 360 recipients of sequential double ACT 
will be monitored for AEs, compared with 180 partic-
ipants on standard ACT. Cardiotoxicity is of general 
safety concern for ACT regimens, and in a multicentre 
African study, it was found that prolonged QTc interval 
occurred in 2.5%–2.6% of ACT-treated children.28 
Using this baseline estimate for our standard treatment 
group, in the pooled analysis of all 1720 participants, we 
have 87.7% power to detect an increase in prevalence 
of prolonged QTc to 6% in the combined sequential 
double ACT groups; with 20% loss to follow-up, power 
of 79.9% to detect this increase is achieved. Exploratory 
analyses, such as impact on QTc interval of the order of 
drug administration, cannot at this stage be evaluated for 
power as reliable estimates of effect size are lacking.
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clinical investigations and laboratory analyses
Clinical investigations will follow the principles of good 
clinical practice. During the trial, the following assess-
ments and sample collections will be performed:
Day 0: Primary diagnosis and enrolment of eligible 
patients providing written informed consent, pretreat-
ment blood sample for microscopy, DNA/RNA analysis 
and drug level measurements (to test for prior antima-
larial use)
Day 0–5: Observed administration of all study drugs; 
questionnaire for AEs
Day 1–6: Clinical assessment; finger-prick blood sample 
for blood film, filter papers for molecular analyses and 
drug measurement
Day 7, 14, 28, 42: Finger-prick for blood films, filter 
papers for molecular analyses and drug measurement; 
questionnaire for AEs (In low transmission settings: also 
day 63)
Passive follow-up: Clinical assessment; finger-prick for 
blood film, molecular analyses and drug measurement at 
any unscheduled presentation; questionnaire for AEs.
Clinical specimens will be stored under standard condi-
tions prior to shipment to the appropriate research 
laboratories. Analyses will follow the principles of good 
clinical and laboratory practice.29–31 These will comprise:
1. Efficacy of the intervention
 ► double-read blood film microscopy results
 ► qPCR clearance profiles on days 0, 1, 2, 3, 4, 5 and 
7 for every study participant27
 ► genotyping for recrudescence/re-infections using 
additional timepoints as described10
 ► QT-nucleic acid sequence-based amplification 
(QT-NASBA) to determine gametocytaemia (days 
0–3, 7, 14, 28, 42, and day 63 for low transmission 
setting)26 32 33
 ► sequence analysis of putative drug resistance loci 
of interest at day 0 and any subsequent follow-up 
timepoints with microscopic or PCR-detected per-
sistent parasitaemia.34
2. Pharmacology
 ► day 0 assessment of blood levels of commonly 
used antimalarials, relevant to local drug use
 ► pharmacokinetics determined from post-treat-
ment blood samples. Concentrations of all rele-
vant partner drugs (lumefantrine, piperaquine, 
amodiaquine) will be measured for each site at all 
timepoints.
3. Safety assessments
 ► monitoring and recording all AEs and severe 
AEs (SAEs), by active (at all visits) and passive 
detection. Any participant with an SAE will be 
withdrawn from the study and offered remedial 
treatment or referred to an appropriate facility
 ► monitoring of haematology and blood chemistry, 
including:
 ► severe anaemia, defined as an Hb <5 g/dL
 ► neutropenia, monitored at day 0, 3, 5 and 7; 
and also at day 14 and/or 28 in case of neutro-
penia <1000/mm3
 ► hepatotoxicity, monitored by standard liver 
function tests (LFTs) at day 3, 7. Cases with 
LFT >5x upper limit of normal (ULN), or ≥3x 
ULN for more than 4 weeks, or with other 
signs, will have additional LFT on day 0 and 
day 28 samples.
 ► Hy’s law cases: among patients with transam-
inase levels >3x ULN on day 3 and/or 7, the 
occurrence of elevated bilirubin (>2x ULN 
and >35% conjugated) without initial findings 
of cholestasis (Alkaline phosphatase (ALP) 
>2x ULN) or other signs of pre-existing liver 
disease will be monitored and recorded.
 ► routine measurement of vital signs at each visit
 ► monitoring QTc by triple ECG at day 0 pre-dose, 
day 2 4–6 hours postdose, day 3 4–6 hours after fi-
nal dose, and on day 28, or when requested by 
a physician. Data will be corrected using both 
Bazett’s and Fridericia’s formulae.
endpoints and outcomes
The primary and main secondary study endpoints derive 
from the objectives, set out above, thus:
 ► parasitological cure on days 28 and 42 (and day 63 
for low transmission setting), stratified by parasite car-
riage status at day 3
 ► absence of moderate or severe AE during follow-up
 ► haematological and biochemical markers of AE re-
maining within acceptable range at days 3 and 7.
Additional secondary endpoints include:
 ► gametocyte carriage identified by QT-NASBA at each 
point during follow-up
 ► qPCR identification of persisting P. falciparum parasi-
taemia at day 3 and day 7
 ► identification of persisting P. falciparum parasitaemia 
at days 28 and 42 (and day 63 in low transmission set-
tings only) by microscopy and PCR
 ► selective occurrence of markers of drug resistance in 
post-treatment samples
 ► estimated adherence to, and acceptability of, pro-
posed treatment schemes.
ethical considerations
The International Conference on Harmonisation Good 
Clinical Practice guidelines will be followed. Scientific 
and ethical review will be sought from local research 
ethics committees and at appropriate European partner 
institutions. Study participants will be enrolled only 
with prior informed consent. Collected data will remain 
confidential. Study results will be reported in aggre-
gated form; study participants will remain anonymous. 
Only the clinical team will access identifiable patients’ 
records. An independent data safety monitoring board 
will be appointed. The trial design will be registered in an 
appropriate trial repository.
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Discussion
The proposed novel protocol seeks to evaluate effi-
cacy and safety of sequential double ACT for treating 
P. falciparum malaria patients in Africa, and to test the 
potential of prolonged ACT regimens against persistent 
parasitaemia.16 17 21 We have designed this approach to maxi-
mise impact, and minimise delay, by deploying licensed 
medicines that could be implemented in sequential 
double ACT relatively swiftly, before emerging resistance 
(should it arise in Africa) becomes a major threat to public 
health.15–17 22 Based on prior experience in the chosen 
study sites, we have targeted children with clinical malaria 
symptoms across a broad age range so as to capture a repre-
sentative profile of paediatiric malaria in each place.
It has been demonstrated that submicroscopic 
persistence of P. falciparum within 3 days of ACT 
treatment is a significant risk factor for subsequent 
recrudescent parasitaemia post-treatment.10 Use of 
sequential double ACT is suggested to reduce or prevent 
the persistence of parasites surviving treatment.17 18 22 
Data from extended duration artesunate monotherapy 
trials,20 35 and the multicentre TRAC study,19 have shown 
that longer duration of artemisinin treatment, but not 
higher dosage, is efficacious against slow-clearing P. 
falciparum genotypes associated with reduced drug effi-
cacy in the Greater Mekong subregion. A short course 
triple combination regimen (triple ACT) is currently 
under trial in that region.36 However, our expectation is 
that extended ACT treatment is more likely to prevent 
parasite persistence and transmission after treatment. 
Development of new antimalarial drugs is crucial but, 
to the best of our knowledge, no newly licensed regi-
mens are ready for widespread deployment in Africa 
in the next half-decade. Sequential double ACT could 
be rapidly deployed as a second-line option in African 
countries, extending the lifetime of current ACT as 
the drug development pipeline generates new antima-
larials in due course. However, the safety profile of the 
proposed extended ACT regimens is unknown; our 
study is designed to provide comprehensive data on the 
occurrence of AE. From these data, we would derive a 
composite safety endpoint, encompassing the range of 
events observed, for future studies.
Should our study find that sequential double ACT is 
well tolerated, and effectively reduces or prevents recur-
rent parasitaemia and transmission in African settings, this 
approach should be considered as a legitimate option for 
treatment of uncomplicated malaria in scenarios where 
drug resistance is a threat to first-line malaria treatments. 
Such scenarios would include:
 ► communities in which the average time between clin-
ical malaria episodes receiving ACT has measurably 
fallen to less than 4 weeks
 ► hospital settings in which severe malaria admissions 
are increasing in number, suggesting failure of the 
malaria drugs supplied by the surrounding primary 
healthcare providers
 ► districts with documented cases of treatment failure, 
in which health authorities wish to undertake a con-
certed effort to eliminate or reduce the prevalence of 
drug-refractory P. falciparum
We do not envisage that sequential double ACT would 
become first-line policy, but rather a second-line strategy 
under these scenarios. However, the potential impact of 
full-scale implementation of sequential double ACT as a 
first-line therapeutic strategy could also be explored. Such 
a strategy will increase the costs of malaria treatment, and 
may also suffer from poor adherence to and acceptability 
of a 6-day treatment course, notwithstanding the 7-day 
quinine treatment that is the current rescue policy in cases 
of ACT failure. Therefore, we would advocate a modelling 
analysis (not included in the current proposal) linked to 
our study to evaluate the cost–benefit ratio of sequential 
double ACT under different conditions of transmission 
intensity and frequency of post-treatment parasitaemia. 
Varying levels of effort to ensure good compliance with 
the sequential double ACT regimens could be tested in 
the model. Similarly, the optimal order of administration 
of sequential double ACT can be explored using in silico 
approaches such as the Simcyp platform.37 On this basis, 
the project will initiate development of treatment guide-
lines for implementation of sequential double ACT under 
each of the indicated scenarios, together with modelling 
outputs designed to inform authorities as to the prevailing 
conditions of transmission intensity and drug efficacy 
under which cost–benefit considerations favour implemen-
tation. This will be integrated into our ‘decision tree’.
An alternative output from our study may be the 
finding that, unlike the situation in Southeast Asia, 
post-ACT persisting parasites in African malaria patients 
are not susceptible to regimens of extended duration. 
This would be an important finding, as it would further 
emphasise the great urgency needed in the search for 
novel antimalarials, the development of effective vaccines 
and continued improvement in non-chemotherapeutic 
malaria control approaches.
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